Original research article| Volume 56, ISSUE 2, P67-75, August 1997

Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 μg ethinyl estradiol and 2.00 mg dienogest on the hemostatic system

      This paper is only available as a PDF. To read, Please Download here.


      Forty healthy female volunteers aged between 19 and 35 years (27.3 ± 4.1 years) with normal menstrual cycles were included in a double-blind, randomized, placebo-controlled study to investigate the influence on the hemostatic system of an oral contraceptive containing 30 μg ethinyl estradiol in combination with 2.00 mg dienogest, which is a 19-norprogestin without a 17α-ethinyl group. At baseline and during one treatment cycle, 12 hemostatic parameters were measured on cycle days 7, 14, and 21. The hemostatic parameters were categorized as either procoagulatory, anticoagulatory and profibrinolytic, or antifibrinolytic and indicative of fibrin turnover. Differences between placebo and 30 μg ethinyl estradiol and 2.00 mg dienogest of plasma levels of hemostatic parameters on cycle days 21 of the precycle and treatment cycle were chosen as target variables. Prothrombin fragment 1 + 2 (F 1 + 2) was chosen as the main target variable. Equivalence of F 1 + 2 between placebo and active treatment was noted. Among the procoagulatory factors, only factor VII activity was found to be increased over placebo in the active treatment group, but decreased in the placebo group. Protein C activity increased during the treatment with 30 μg ethinyl estradiol and 2.00 mg dienogest, and was higher than that of the placebo group in which this parameter decreased during the treatment cycle. There was a corresponding increase in fibrinolytic activity being reflected by higher plasminogen levels in the active treatment group in comparison with placebo. An increase was noted for the fibrinolytic parameter d-dimer. Apart from isolated measurements, the parameters remained in their respective normal ranges. The data combine to suggest that 30 μg ethinyl estradiol and 2.00 mg dienogest has a balanced effect on the hemostatic system stimulating both procoagulatory and fibrinolytic activity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Inman WHV
        • Vessey MP
        • Westerholm B
        • Engelund MN
        Thromboembolic diseases and steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.
        Br Med J. 1970; 2: 203-209
        • Shapiro S
        Oral contraceptives—a time to take stock.
        N Engl J Med. 1986; 315: 450-451
        • Gerstman BB
        • Piper JM
        • Tomita DK
        • et al.
        Oral contraceptive estrogen dose and risk of deep venous thromboembolic disease.
        Am J Epidemiol. 1991; 133: 32-36
        • Lidegaard O
        Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.
        Br Med J. 1993; 306: 956-963
        • Mishell Jr, DR
        Oral contraception: past, present and future perspectives.
        Int J Fertil. 1991; 36: 7-18
        • Helmrich SP
        • Rosenberg L
        • Kaufmann DW
        • Strom B
        • Shapiro S
        Venous thromboembolism in relation to oral contraceptive use.
        Obstet Gynecol. 1987; 69: 91-95
        • Fotherby K
        • Caldwell ADS
        New progestogens in oral contraception.
        Contraception. 1994; 49: 1-32
        • Daly I
        • Bonnar J
        Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets.
        Am J Obstet Gynecol. 1990; 163: 430-437
        • Winkler UH
        • Koslowski S
        • Schindler AE
        PAI activity is reduced in users of oral contraceptives—influence of estrogen content.
        Thromb Haemost. 1989; 62: 394
        • Bottiger LE
        • Boman G
        • Eklund G
        • Westerholme B
        Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content.
        Lancet. 1980; i: 1097-1101
        • Meade TW
        • Greenberg G
        • Thompson SC
        Progestogens and cardiovascular reactions associated with oral contraceptives and comparison of the safety of 50 and 30 μg oestrogen preparations.
        Br Med J. 1980; i: 1157-1161
        • Kierkegaard A
        Deep-vein thrombosis and the oestrogen content in oral contraceptives. Annual epidemiological analysis.
        Contraception. 1985; 31: 29-41
        • Jespersen J
        • Petersen KR
        • Skouby SO
        Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid.
        Am J Obstet Gynecol. 1990; 163: 396-403
        • Meade TW
        Oral contraceptives, clotting factors and thrombosis.
        Am J Obstet Gynecol. 1982; 142: 758-761
        • Sabra A
        • Bonnar J
        Haemostatic system changes induced by 50 μg and 30 μg oestrogen/progestogen oral contraceptives. Modification of oestrogen effects by levonorgestre.
        J Reprod Med. 1983; 28 (suppl): 85-91
        • Daly L
        • Bonnar J
        Comparative studies of 30 μg ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
        Am J Obstet Gynecol. 1990; 163: 430-437
        • Bonnar J
        • Daly L
        • Carroll E
        Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
        Int J Fertil. 1987; 32 (suppl): 21-28
        • Bonnar J
        Coagulation effects of oral contraception.
        Am J Obstet Gynecol. 1987; 157: 1042-1048
        • Oettel M
        • Carol W
        • Elger W
        • et al.
        A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view.
        Drugs of Today. 1995; 31: 517-536
        • Oettel M
        • Bervoas-Martin B
        • Elger W
        • et al.
        A 19-norprogestin without a 17α-ethinyl group. I: Dienogest from a pharmacokinetic point of view.
        Drugs of Today. 1995; 31: 499-516
        • Moore C
        • Walter F
        • Klinger G
        • et al.
        Der Einfluss von Dienogest auf die Ovulation junger Frauen und auf weitere ausgewählte endokrinologische Parameter.
        in: Teichmann AT Dienogest—Präklinik und Klinik eines neuen Gestagens. Walter de Gruyter, New York1955: 161-171
        • Winkler UH
        • Schindler AE
        • Endrikat J
        • Düsterberg B
        A comparative study of the effects on the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol.
        Contraception. 1996; 53: 75-84
        • Wellek S
        3rd edition. Statistische Methoden zum Nachweis von Aquivalenz. Gustav Fischer, Stuttgart, Germany1994
        • Beller FK
        Cardiovascular system: Coagulation, thrombosis, and contraceptive steroids—is there a link?.
        in: Goldzieher JW Fotherby K Pharmacology of the Contraceptive Steroids. Raven Press, New York1994: 309-333
        • Mannuci PM
        • Bottaso B
        • Tripodi A
        Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants.
        Thromb Haemost. 1991; 66: 741-745
        • Abbate R
        • Pinto S
        • Rostango C
        • et al.
        Effects of long-term gestodene oral contraceptive administration on hemostasis.
        Am J Obstet Gynecol. 1990; 163: 424-429
        • David JL
        • Gaspard WJ
        • Gillian D
        • et al.
        Hemostatic profile in women taking low-dose oral contraceptives.
        Am J Obstet Gynecol. 1990; 163: 420-423
        • Prasad RNV
        • Koh S
        • Ratnam SS
        Effects of three types of oral contraceptives on blood coagulation, fibrinolysis and platelet function.
        Contraception. 1989; 39: 368-383
        • Ball MJ
        • Ashwell E
        • Jackson M
        • Gillmer MGD
        Comparison of two triphasic contraceptives on metabolism and coagulation proteins.
        Contraception. 1990; 4: 363-370
        • Malm J
        • Laurell M
        • Dehlback B
        Changes in plasma levels of proteins C and S during pregnancy and oral contraception.
        Br J Haematol. 1988; 8: 437-443
        • Gilabert J
        • Fernandez JA
        • Espana F
        • et al.
        Physiological coagulation inhibitors (protein S and C, AT III) in severe pre-eclamptic states and users of oral contraceptives.
        Thromb Res. 1987; 49: 319-329
        • Huisveld IA
        • Hospers JE
        • Meijers JC
        • et al.
        Oral contraceptives reduce total protein S but not free protein S.
        Thromb Res. 1987; 45: 109-114
        • Hirvonen E
        • Stenman UH
        • Malkonen A
        • et al.
        New estradiol/cyproterone acetate oral contraceptive for premenopausal women.
        Maturitas. 1988; 10: 201-213
        • Bruno V
        • Rosaki D
        • Bucciantini S
        • et al.
        Wirkungen eines antiandrogenen Kombinationspräparates auf das hämostatische System.
        Fortschr Med. 1987; 5: 55-58
        • Winkler VH
        • Buhler K
        • Schindler AE
        The dynamic balance of hemostasis: implications for the risk of oral contraceptive use.
        in: Runnebaum B Rabe E Kiesel L Female contraception and fertility regulation. Parthenon Publishing Group, Park Ridge, Illinois1991: 21-34